Flagship Pioneering launched Serif Biomedicines with an initial USD 50 million commitment to develop a new class of modified DNA-based medicines, the company announced. Flagship is a Massachusetts-based biotech that creates, funds, and builds new life sciences companies, previously behind the formation of companies such as Moderna, Seres Therapeutics, and Tessera Therapeutics.
Serif said its platform integrates multiple components designed to improve the performance and flexibility of DNA-based therapeutics. These include chemically modified DNA constructs engineered to reduce innate immune activation, alongside co-delivered mRNA factors intended to enhance nuclear entry and gene expression efficiency. The system is supported by optimized lipid nanoparticle (LNP) delivery technologies designed to enable repeat dosing and targeted tissue distribution, as well as AI-guided sequence design to support cell-specific, programmable gene expression.
The company said the approach is intended to address limitations across existing modalities, including the transient expression typically associated with mRNA therapies, redosing constraints in gene therapy, and the reliance on genomic integration in some gene editing strategies. Serif is also developing scalable manufacturing processes aimed at improving cost efficiency and broadening access if the platform advances to clinical use. Initial data cited by the company come from preclinical studies, including non-human primate models. No human clinical data have been reported. Serif plans to initially focus on rare diseases and immune-related conditions, though it has not disclosed specific pipeline candidates.
Serif is positioning modified DNA as a potential new therapeutic modality, though its clinical utility remains to be established as the platform advances toward human studies.